# A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

> **NCT06186076** · PHASE1,PHASE2 · TERMINATED · sponsor: **Therapex Co., Ltd** · enrollment: 19 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- EGFR Mutant Advanced Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** TRX-221

## Key facts

- **NCT ID:** NCT06186076
- **Lead sponsor:** Therapex Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-06-14
- **Primary completion:** 2025-12-03
- **Final completion:** 2025-12-03
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Sponsor's decision
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06186076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06186076, "A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06186076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*